medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2005; 52 (4)

VPH infection and uterine cancer

Sánchez HJA, Huerta PMI, Rivera TJA, Rosales PM

Language: Spanish
References: 32
Page: 222-233
PDF size: 144.54 Kb.


ABSTRACT

The cervix uterine cancer is one of the biggest problems in public health in Latin America. Although there is an effective technology for the secondary prevention of this condition, more than 30 000 Latin Americans die for this cause yearly. Currently it is believed that the invasive form of cervix uterine cancer is strongly related with the human papilloma virus; At the present there are more than 80 types, classified as of high, medium and low risk. It has been deepened in their behavior as sexual transmission illness as in their potential of producing the transformation from infected cells to malignant cells, suggesting that the oncogenic types are responsible of more than 90% of all the cervix uterine cancers and their precursors. It is accepted that the infection by the virus precedes to the cervical intraepithelial neoplasia (CIN), and as all the sexual transmission illnesses (STI), it has direct relationship with the beginning of the sexual activity and the number of sexual partners, which has been favored for the appearance of the oral contraceptives and consequently people have stopped using condom. Despite the development of molecular biology techniques which have made possible to tipify the virus and the recognition of the varieties of high oncogenic risk that has a great value of prediction, these are not within reach of all the patients in the daily practice. In our country the diagnosis of these infections is mainly based on the triad citology-colposcopic-biopsy, favored by the National Program of Early Diagnostic of the Cervix Uterine Cancer. This shows very good results about investigation of the cancer in curable stages, but without success in the decrease of the mortality. Following the regulations, the compatible low degree lesions with CIN I and those of high degree are object of study, treatment and monitoring. However, women are only included from 25 to 60 for the investigation, because the incidence of this pathology has been bigger among this age range.


REFERENCES

  1. Castellanos MR. Cáncer cervicouterino y el VPH. Opciones de detección. Rev Fac Med UNAM 2003; 46: 63-66.

  2. Kersemaekers AMF. Oncogene alterations in carcinomas of uterine: Overexpression of the epidermal growth factor receptor is association with poor Prognosis. Clin Resch 1999; 5: 577-586.

  3. Lazcano-Ponce EC, Moss S, Alonso P, Salmeron J, Hernandez M. Cervical cancer screening in developing countries : why is it ineffective? The case of Mexico. Arch Med Res 1999; 30: 240-250.

  4. Ndisang D, Budhram-Mahadeo V, Latchman DS. The Brn-3a transcription factor plays a critical role in regulating human papilloma virus gene expression and determining the growth characteristics of cervical cancer cells. J Biol Chem 1999; 274: 28521-28527.

  5. Patti E, James V, Louise A et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Epidemiol Biomark Prev 2001; 10: 95-100.

  6. Torriente B, Martínez RV. Aplicación del Interferón en el tratamiento de la infección por virus del papiloma humano. Rev Cub Obstet Ginecol 2002; 28: 15-20.

  7. Tapia C, Sandoval RJ, Garcia GA, Durán A. Cáncer cervicouterino: Factores de riesgo y alteraciones asociadas en mujeres del estado de Guerrero. Rev Ins Nal Cancerol Mex 1998; 44: 19-27.

  8. Aguirre R, Alvárez C, Briozzo L, Varela R. Carcinoma verrugoso y carcinoma condilomatoso de vulva. Dos lesiones distintas desde el punto de vista histológico epidemiológico y clínico. Arch Ginecol Obst 2001; 39: 20-27.

  9. Traiman P, Bacchi CE, De Luca LA. Vulvar carcinoma in young patients and its relationship with genital warts. Eur J Gynaecol Oncol 1999; 20: 191-194.

  10. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nature Rev 2004; 4: 46-54.

  11. Velázquez RF, Pacheco C, Calderón F. Utilidad de la circuncisión en combinación con 5-fluorouracilo en el tratamiento de la infección subclínica por papilomavirus humano. Rev Mex Urol 1993; 53: 19-24.

  12. Zhang A, Maner S, Betz R, Ángstrom T. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 2002; 101:427-433.

  13. Zur Hausenm H, De Villiers EM, Gissmann L. Papillomavirus infections and human genital cancer. Gynecol Oncol 1981; 12: 124-128.

  14. Janicek ME, Averette HE. Prevención y diagnóstico del cáncer de cuello. CA Cáncer J Clin 2001; 51: 92-144.

  15. Burger RA, Monk BJ, Kurosaki T. Human papilloma virus type 18: Association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88: 1361-1368.

  16. Bosh FX, Mnos MM, Muñoz N, Shrman M, Jansen AM, Peto J. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995; 87: 796-802.

  17. Muñoz M, Mendoza JA, Tellez L. Detección de VPH-16 y 18 en muestras de cérvix de mujeres que acuden a centros asistenciales de la ciudad de Mérida, Venezuela.

  18. Brisson J, Morin C, Fortier M. Risk factors for cervical intraepithelial neoplasia: Differences between low and high-grade lesions. Am J Epidemiol 1994; 140: 700-710.

  19. Eluf-Neto J, Booth M, Bosch FX, Meijer CJ. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994; 69:114-119.

  20. Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B, Hagmar B. J Clin Microbiol 1996; 34: 2095-2100.

  21. Lazcano E, Nájera P, Alonso P, Buitti E, Hernández M. Programa de Detección Oportuna de Cáncer Cervical en México. Diagnóstico situacional. Rev Inst Nal Cancerol Mex 1996; 42:123-140.

  22. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Aryeux P, Seillles E, Mougin C. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by hybrid capture II and polymerase chain reaction. Diagn Mol Pathol 1999; 8: 157-164.

  23. Walboomers JMM, Jacobs MV, Manos MM. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.

  24. Ganén PI. Cancer y virus. Revisiones Bibliográficas de la Facultad de Ciencias Médicas Provincia Guantánamo 1997; 5: 23-27.

  25. Janicek FM, Averette HE. Cervical cancer: Prevention, diagnosis and therapeutics. CA Cancer J Clin 2001; 51: 92-114.

  26. Burns AKJ et al. Detection of low copy human papilloma virus DNA and RNA in routine paraffin sections of cervix by non-isotopic in situ hybridization. J Clin Pathol 1987; 40: 858-864.

  27. Ostrow RS, Manias DA, Clark BA, Okagaki T, Twiggs LB, Faras AJ. Detection of human papilloma virus DNA invasive carcinomas of cervix by in situ hybridization. Cancer Res 47: 649-653.

  28. Roda A et al. Microtiter format for simultaneous multianalyte detection and development of a PCR-chemiluminescent enzyme immunoassay for typing human papillomavirus DNAs. Clin Chem 2002; 54: 1654-1660.

  29. Jastreboff AM, Cymet T. Role of the human papilloma virus in the development of cervical intraepithelial neoplasia and malignancy. PMJ Online 2002; 78: 225-228.

  30. Bates S, Vousden KH. P53 in signalling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996; 6: 12-19.

  31. Evander M, Frazer IH, Pyne E, Qi YM, Hengst K, McMillan NAJ. Identification of the a6 integrin as a candidate receptor for papillomaviruses. J Virol 1997; 71: 2449-2456.

  32. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-292.




2020     |     www.medigraphic.com